Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II

NCT01309672 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT01309672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01309672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
August 9, 2011
Completion date
April 11, 2024
Enrollment
41 (actual)
Sites
205

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer